An oncolytic group B adenovirus suitable for treating a solid tumor (for example sarcoma, carcinoma and/or lymphoma) comprising a sequence of formula (I): 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR (I) wherein: a first transgene encodes a polypeptide comprising a target-sequence specific for a binding domain on the cells of a cell-based immunotherapy, for example bearing a (exogenous) recombinant surface expressed protein, such as a chimeric antigen receptor or an NKG2D receptor, in particular wherein the target-sequence specifically binds to said surface expressed protein (more especially the chimeric antigen receptor) on the immunotherapy cell; and a second transgene encodes a polypeptide comprising a molecule that promotes trafficking of the cell-based immunotherapy into and within the tumor.
Provided are engineered cancer antigens and uses of such engineered cancer antigens for treating cancer, such as in combination with a chimeric antigen receptor therapy that recognizes the engineered cancer antigen on tumor cells.
A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell activator comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
The present disclosure relates to formulations suitable for the storage of group B adenoviruses, such as Enadenotucirev (EnAd), processes for making the formulations, and use of the formulations in methods of treatment.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
5.
ONCOLYTIC ADENOVIRUSES ARMED WITH HETEROLOGOUS GENES
The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR wherein: B1 is a bond or comprises: E1A, E1B or E1A-E1B; BA comprises: E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises: L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
The present disclosure relates to a replication deficient oncolytic viral vector or replication capable group B oncolytic adenovirus selected from the group consisting of Ad11 and enadenotucirev, wherein the virus encodes an antibody or a binding fragment thereof for expression on the surface of a cancer cell, wherein said antibody or binding fragment is specific to a CD3 protein of a T-cell receptor complex (TCR), wherein the virus does not encode a B7 protein or an active fragment thereof, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 35/768 - Virus oncolytiques non prévus dans les groupes
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A group B adenovirus comprising a sequence of formula 5′ITR—B1-BA-B2-BX-BB-BY-B3-3′ITR, wherein: BY comprises a sequence -G1-G2n-G3m-G4p-G5q. G1 is a first transgene. G2 is a second transgene. G3 is a third transgene. G4 is a fourth transgene. G5 is a fifth transgene and IL-15 is encoded as a transgene in at least one of said locations, and characterised in that BY also encodes a polypeptide comprising the sushi domain of IL-15R alpha.
An adenovirus comprising a sequence of formula (I): 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR (I) wherein BY comprises a transgene cassette containing four transgenes, said genes encoding a FAP-Bispecific T cell activator, CXCL10, CXCL9, and IFN. The disclosure also extends to pharmaceutical composition comprising the virus, and use of the virus or formulation in treatment
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
9.
VIRUS ENCODING TRANSGENES TO COMPLEMENT CELLULAR THERAPY
An oncolytic group B adenovirus suitable for treating a solid tumour (for example sarcoma, carcinoma and/or lymphoma) comprising a sequence of formula (I): 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR (I) wherein: a first transgene encodes a polypeptide comprising a target-sequence specific for a binding domain on the cells of a cell-based immunotherapy, for example bearing a (exogenous) recombinant surface expressed protein, such as a chimeric antigen receptor or an NKG2D receptor, in particular wherein the target-sequence specifically binds to said surface expressed protein (more especially the chimeric antigen receptor) on the immunotherapy cell; and a second transgene encodes a polypeptide comprising a molecule that promotes trafficking of the cell-based immunotherapy into and within the tumour.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Biological preparations for the diagnosis and treatment of oncological diseases and disorders; biological preparations for treating tumors; medicinal preparations for use in oncology; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for treating malignant tumors; (1) Biochemical research and analysis; biological therapeutic research services; biomedical research services; consultancy in the field of biochemistry; consultancy pertaining to pharmacology; consulting services in the field of pharmaceutical research; development of pharmaceutical preparations and medicines; genetic testing for scientific research purposes; pharmaceutical drug development services; pharmaceutical research and development; pharmaceutical research services; research and analysis in the field of medicine; research and development in the medical biotechnology field; research and development of vaccines and medicines; research and development services in the field of immunology; research in the field of gene therapy; scientific research for medical purposes in the field of oncology
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Biological preparations for the diagnosis and treatment of oncological diseases and disorders; biological preparations for treating tumors; medicinal preparations for use in oncology; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for treating malignant tumors; (1) Biochemical research and analysis; biological therapeutic research services; biomedical research services; consultancy in the field of biochemistry; consultancy pertaining to pharmacology; consulting services in the field of pharmaceutical research; development of pharmaceutical preparations and medicines; genetic testing for scientific research purposes; pharmaceutical drug development services; pharmaceutical research and development; pharmaceutical research services; research and analysis in the field of medicine; research and development in the medical biotechnology field; research and development of vaccines and medicines; research and development services in the field of immunology; research in the field of gene therapy; scientific research for medical purposes in the field of oncology
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical compositions for the treatment of oncological diseases and disorders; biotechnological preparations for medical use; biotechnological preparations for the treatment of oncological diseases and disorders; biotechnological preparations for the medical treatment of solid tumors.. Business management in the field of pharmaceutical products; business management consultancy in the field of pharmaceutical products; business information in the field of pharmaceutical products; marketing in the field of pharmaceutical products; product marketing in the field of pharmaceutical products; market research in the field of pharmaceutical products; market forecasting in the field of pharmaceutical products; market evaluation in the field of pharmaceutical products; pharmaceutical product marketing; retail or wholesale services in relation to pharmaceutical products; retail or wholesale services in relation to pharmaceutical preparations; online retail or wholesale services in relation to pharmaceutical products; online retail or wholesale services in relation to pharmaceutical preparations; advisory, information and consultancy services relating to the aforementioned services.. Pharmaceutical research and development services; pharmaceutical drug development services; research and development of new pharmaceutical products for others; biomedical research service; medicine development services; pharmaceutical research; biochemical research and analysis; clinical trials; genome organization and functional analysis; genetic testing for scientific research; research and development services in the field of immunology, biotechnology, oncology, medicine, gene therapy, immunotherapy and therapeutics; technological services related to manufacture of pharmaceuticals; design of manufacturing methods for pharmaceuticals; advisory, information and consultancy services relating to the aforementioned services..
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical compositions for the treatment of oncological diseases and disorders; biotechnological preparations for medical use; biotechnological preparations for the treatment of oncological diseases and disorders; biotechnological preparations for the medical treatment of solid tumors.. Business management in the field of pharmaceutical products; business management consultancy in the field of pharmaceutical products; business information in the field of pharmaceutical products; marketing in the field of pharmaceutical products; product marketing in the field of pharmaceutical products; market research in the field of pharmaceutical products; market forecasting in the field of pharmaceutical products; market evaluation in the field of pharmaceutical products; pharmaceutical product marketing; retail or wholesale services in relation to pharmaceutical products; retail or wholesale services in relation to pharmaceutical preparations; online retail or wholesale services in relation to pharmaceutical products; online retail or wholesale services in relation to pharmaceutical preparations; advisory, information and consultancy services relating to the aforementioned services.. Pharmaceutical research and development services; pharmaceutical drug development services; research and development of new pharmaceutical products for others; biomedical research service; medicine development services; pharmaceutical research; biochemical research and analysis; clinical trials; genome organization and functional analysis; genetic testing for scientific research; research and development services in the field of immunology, biotechnology, oncology, medicine, gene therapy, immunotherapy and therapeutics; technological services related to manufacture of pharmaceuticals; design of manufacturing methods for pharmaceuticals; advisory, information and consultancy services relating to the aforementioned services..
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical compositions for the treatment of oncological diseases and disorders; biotechnological preparations for medical use; biotechnological preparations for the treatment of oncological diseases and disorders; biotechnological preparations for the medical treatment of solid tumors.. Business management in the field of pharmaceutical products; business management consultancy in the field of pharmaceutical products; business information in the field of pharmaceutical products; marketing in the field of pharmaceutical products; product marketing in the field of pharmaceutical products; market research in the field of pharmaceutical products; market forecasting in the field of pharmaceutical products; market evaluation in the field of pharmaceutical products; pharmaceutical product marketing; retail or wholesale services in relation to pharmaceutical products; retail or wholesale services in relation to pharmaceutical preparations; online retail or wholesale services in relation to pharmaceutical products; online retail or wholesale services in relation to pharmaceutical preparations; advisory, information and consultancy services relating to the aforementioned services.. Pharmaceutical research and development services; pharmaceutical drug development services; research and development of new pharmaceutical products for others; biomedical research service; medicine development services; pharmaceutical research; biochemical research and analysis; clinical trials; genome organization and functional analysis; genetic testing for scientific research; research and development services in the field of immunology, biotechnology, oncology, medicine, gene therapy, immunotherapy and therapeutics; technological services related to manufacture of pharmaceuticals; design of manufacturing methods for pharmaceuticals; advisory, information and consultancy services relating to the aforementioned services..
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical compositions for the treatment of oncological diseases and disorders; biotechnological preparations for the medical treatment of solid tumors; biotechnological preparations for the treatment of oncological diseases and disorders Marketing services in the field of pharmaceutical products; product marketing services in the field of pharmaceutical products;
market research in the field of pharmaceutical products; market forecasting in the field of pharmaceutical products; market
evaluation services, namely, market analysis and research services in the field of pharmaceutical products; online retail and
wholesale store services for pharmaceutical products; online retail and wholesale store services for pharmaceutical preparations;
advisory, information and consultancy services relating to the aforementioned services Pharmaceutical research and development services; pharmaceutical drug development services; research and development of
new pharmaceutical products for others; biomedical research services; medicine development service; pharmaceutical research;
biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; scientific and medical
research in the nature of genome organization and functional analysis; genetic testing for scientific research purposes; research
and development services in the field of immunology, biotechnology, oncology, medicine, gene therapy, immunotherapy and
therapeutics; technological consulting services, namely, product development consultation relating to the manufacture of
pharmaceuticals; technological consulting services, namely, product development consultation relating to the design of
manufacturing methods for pharmaceuticals; advisory, information and consultancy services relating to the aforementioned
services
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical compositions for the treatment of oncological diseases and disorders; biotechnological preparations for the medical treatment of solid tumors; biotechnological preparations for the treatment of oncological diseases and disorders Marketing services in the field of pharmaceutical products; product marketing services in the field of pharmaceutical products;
market research in the field of pharmaceutical products; market forecasting in the field of pharmaceutical products; market
evaluation services, namely, market analysis and research services in the field of pharmaceutical products; online retail and
wholesale store services for pharmaceutical products; online retail and wholesale store services for pharmaceutical preparations;
advisory, information and consultancy services relating to the aforementioned services Pharmaceutical research and development services; pharmaceutical drug development services; research and development of
new pharmaceutical products for others; biomedical research services; medicine development service; pharmaceutical research;
biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; scientific and medical
research in the nature of genome organization and functional analysis; genetic testing for scientific research purposes; research
and development services in the field of immunology, biotechnology, oncology, medicine, gene therapy, immunotherapy and
therapeutics; technological consulting services, namely, product development consultation relating to the manufacture of
pharmaceuticals; technological consulting services, namely, product development consultation relating to the design of
manufacturing methods for pharmaceuticals; advisory, information and consultancy services relating to the aforementioned
services
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical compositions for the treatment of oncological diseases and disorders; biotechnological preparations for the medical treatment of solid tumors; biotechnological preparations for the treatment of oncological diseases and disorders Marketing services in the field of pharmaceutical products; product marketing services in the field of pharmaceutical products; market research in the field of pharmaceutical products; market forecasting in the field of pharmaceutical products; market evaluation services, namely, market analysis and research services in the field of pharmaceutical products; online retail and wholesale store services for pharmaceutical products; online retail and wholesale store services for pharmaceutical preparations; advisory, information and consultancy services relating to the aforementioned services Pharmaceutical research and development services; pharmaceutical drug development services; research and development of new pharmaceutical products for others; biomedical research services; medicine development service; pharmaceutical research; biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; scientific and medical research in the nature of genome organization and functional analysis; genetic testing for scientific research purposes; research and development services in the field of immunology, biotechnology, oncology, medicine, gene therapy, immunotherapy and therapeutics; technological consulting services, namely, product development consultation relating to the manufacture of pharmaceuticals; technological consulting services, namely, product development consultation relating to the design of manufacturing methods for pharmaceuticals; advisory, information and consultancy services relating to the aforementioned services
18.
METHOD OF PURIFYING A COMPOSITION COMPRISING A GROUP B ADENOVIRUS
A method of purifying a composition comprising a group B adenovirus, for example comprising a purification step of: subjecting a composition comprising said group B adenovirus to diafiltration employing a diafiltration-buffer with a conductivity of at least 180 mScm−1, for example a conductivity of 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, or 290 mScm−1. Also provided is a composition obtained using the purification method disclosed herein.
12 particles per minute. The disclosure further extends to formulations of the oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
The present disclosure provides a liquid formulation suitable for a group B adenovirus, comprising: a) a group B adenovirus, such as replication competent group B adenovirus, b) 15 to 25% v/v glycerol, for example 16, 17, 18, 19, 20, 21% v/v glycerol; and c) 0.1 to 1.5% v/v ethanol, for example 0.2-1%, such as 1% v/v ethanol; and d) a buffer, and e) optionally an amino acid, wherein the pH of the formulation is in the range 8.0 to 9.6, and use of the same in treatment, particular in the treatment of cancer.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
Y comprises a transgene cassette containing four transgenes, said genes encoding a FAP-Bispecific T cell activator, CXL10, CXL9, and IFN. The disclosure also extends to a pharmaceutical composition comprising the virus, and use of the virus or formulation in treatment.
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
An oncolytic virus (for example a replication competent virus) comprising a transgene cassette encoding an anti-CD40 antibody or binding fragment thereof, wherein the transgene cassette comprises an amino acid sequence given in SEQ ID NO: 12 or a sequence at least 95% identical thereto (such as 96, 97, 98 or 99% identical thereto), in particular a cassette of SEQ ID NO: 12; pharmaceutical compositions comprising the same, methods of preparing said oncolytic virus and compositions and use of the oncolytic virus or composition in treatment, in particular in the treatment of cancer. Also provided is the treatment of a patient population characterised as having a cancer expressing CD40, in particular a cancer over expressing CD40, with a therapy according to the present disclosure.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A modified adenovirus, in particular Enadenotucirev (EnAd), armed with at least two bispecific T cell engagers each comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on an immune cell of interest, such as a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell activator comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
The present disclosure relates to a replication deficient oncolytic viral vector or replication capable group B oncolytic adenovirus selected from the group consisting of Ad11 and enadenotucirev, wherein the virus encodes an antibody or a binding fragment thereof for expression on the surface of a cancer cell, wherein said antibody or binding fragment is specific to a CD3 protein of a T-cell receptor complex (TCR), wherein the virus does not encode a B7 protein or an active fragment thereof, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.
A61K 35/768 - Virus oncolytiques non prévus dans les groupes
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
28.
Virus encoding an anti-TCR-complex antibody or fragment
The present disclosure relates to a replication deficient oncolytic viral vector or replication capable oncolytic virus encoding an antibody or a binding fragment thereof to the antigen-specific T-cell receptor complex (TCR) for expression on the surface of a cancer cell, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 35/768 - Virus oncolytiques non prévus dans les groupes
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and substances. Research and development services in the field of immunology, biotechnology, oncology, medicine and therapeutics.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
pharmaceutical preparations and substances. Research and development services in the field of immunology, biotechnology, oncology, medicine and therapeutics.
The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders Pharmaceutical research and development services in the field of immunology, biotechnology, oncology, and therapeutics
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders Pharmaceutical research and development services in the field of immunology, biotechnology, oncology, and therapeutics
The present disclosure provides a oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a membrane anchored anti-CD3 antibody or a binding fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
39.
Oncolytic adenovirus encoding a B7 protein or active fragment
The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5′ITR-B1-BAB2-BX-BB-BY-B3-3′ITR wherein: B1 is bond or comprises: E1A, E1B or E1AE1B; BA comprises: E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
The present disclosure relates to a method of making an adenovirus plasmid comprising a part or all of an adenovirus genome and one or more original restriction sites allowing rapid and flexible manipulation of the adenovirus genome, and methods of preparing adenovirus constructs, for example comprising a transgene. The disclosure also extends to novel intermediates employed in and generated by the method, to plasmids and shuttle vectors of the method and to adenoviruses or adenoviral vectors obtainable from the plasmid and/or method. The disclosure further relates to use of the viruses or vectors, for example obtained from a method disclosed herein, in therapy, such as use in the treatment of cancer.
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A01K 67/00 - Élevage ou obtention d'animaux, non prévus ailleursNouvelles races ou races modifiées d'animaux
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
43.
Dosing regime and formulations for type B adenovirus
12 particles per minute. Also provided are formulations of the oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
The present disclosure relates to a group B adenovirus comprising a sequence of formula (l):5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITRwherein:B1 is bond or comprises: E1A, E1B or E1A-E1B;BA comprises-E2B-L1-L2-L3-E2A-L4;B2 is a bond or comprises: E3;BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both;BB comprises L5;BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both;B3 is a bond or comprises: E4;wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
The present disclosure relates to a replication deficient oncolytic viral vector or replication capable group B oncolytic adenovirus selected from the group consisting of Ad11 and enadenotucirev, wherein the virus encodes an antibody or a binding fragment thereof for expression on the surface of a cancer cell, wherein said antibody or binding fragment is specific to a CD3 protein of a T-cell receptor complex (TCR), wherein the virus does not encode a B7 protein or an active fragment thereof, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
An oncolytic virus (for example a replication competent virus) comprising a transgene cassette encoding an anti-CD40 antibody or binding fragment thereof, wherein the transgene cassette comprises an amino acid sequence given in SEQ ID NO: 12 or a sequence at least 95% identical thereto (such as 96, 97, 98 or 99% identical thereto), in particular a cassette of SEQ ID NO: 12; pharmaceutical compositions comprising the same, methods of preparing said oncolytic virus and compositions and use of the oncolytic virus or composition in treatment, in particular in the treatment of cancer. Also provided is the treatment of a patient population characterised as having a cancer expressing CD40, in particular a cancer over expressing CD40, with a therapy according to the present disclosure.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
An adenovirus comprising a sequence of formula (I) 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR wherein ?? comprises a transgene cassette containing four transgenes, said genes encoding a FAP- BITE, CXLI O, CXL9, and IFN. The disclosure also extends to pharmaceutical composition comprising the virus, and use of the virus or formulation is treatment.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
A group B adenovirus comprising a sequence of formula 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR, wherein: By comprises a sequence -G1-G2n-G3m-G4p-G5q. G1 is a first transgene. G2 is a second transgene. G3 is a third transgene. G4 is a fourth transgene. G5 is a fifth transgene and IL-15 is encoded as a transgene in at least one of said locations, and characterised in that BY also encodes a polypeptide comprising the sushi domain of IL-15R alpha.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
53.
A DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES
The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1x1010 to 1x1014 viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 2x1010 particles per minute to 2x1012 particles per minute. The disclosure further extends to formulations of the said oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.
A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell engager (BiTE) comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
56.
A DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES
The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1x1 01 to 1x1014 viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 2x101 particles per minute to 2x1012 particles per minute. The disclosure further extends to formulations of the said oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.
